.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Abbott recently announced the launch of its TriClip TEER system in India. This technology represents a major shift in managing tricuspid regurgitation (TR), often called a leaky heart valve. Because TR often affects patients unsuitable for surgery, this device offers a vital alternative. Consequently, Indian cardiologists now have a specialized tool for right-sided heart valve repair.
The system utilizes a transcatheter edge-to-edge repair technique. Specifically, doctors deliver the device through a vein in the leg. Once it reaches the heart, the clip pulls the valve leaflets together. This action reduces the backflow of blood significantly. Because the procedure is minimally invasive, most patients return home after just one day in the hospital.
The USFDA approved this technology based on the TRILUMINATE Pivotal trial. This study showed that 90% of patients experienced a reduction in TR severity. Furthermore, these benefits remained stable during a one-year follow-up period. Two-year data also indicated a 28% reduction in heart failure hospitalizations. Therefore, the device offers long-term improvements in quality of life for those with severe valve leakage.
In India, TR is frequently linked to rheumatic heart disease and atrial fibrillation. However, clinicians often overlook this condition because symptoms develop slowly. Patients might only notice fatigue or shortness of breath as the disease progresses. Consequently, early intervention with the TriClip TEER system could prevent complications like heart failure or permanent organ damage.
Q1: Who is an ideal candidate for the TriClip procedure?
Patients with symptomatic severe tricuspid regurgitation who are at intermediate or high risk for traditional open-heart surgery are typical candidates.
Q2: How long is the recovery period after the procedure?
Most patients require only about a day of hospitalization and can return to their daily activities much faster than after open surgery.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Abbott introduces the TriClip TEER system in India, offering a minimally invasive option for treating leaky tricuspid valves without open-heart surgery....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
